As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/18/15  Sanofi                            6-K         3/18/15    5:122K                                   Merrill Corp-MD/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current Report by a Foreign Private Issuer          HTML     26K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     20K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     32K 
 4: EX-99.3     Miscellaneous Exhibit                               HTML     10K 
 5: EX-99.4     Miscellaneous Exhibit                               HTML     10K 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of March 2015

 

Commission File Number: 001-31368

 

SANOFI

(Translation of registrant’s name into English)

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x                                                                      Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o                                                                                                                                                             No x

 

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82-         

 

 

 

In March 2015, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.4 which are incorporated herein by reference.

 

Exhibit List

 

Exhibit No.		Description
Exhibit 99.1		Press release dated March 17 , 2015: Shantha will provide up to 37 million doses of Shan5™
Exhibit 99.2		Press release dated March 15 , 2015: Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine
Exhibit 99.3		Press release dated March 12, 2015: Filing of the 2014 U.S. Form 20-F and French “Document de Référence” containing the Annual Financial Report
Exhibit 99.4		Press release dated March 6, 2015: Sanofi Appoints Robert Castaigne as Audit Committee Chairman

 

2

 

Exhibit Index

 

Exhibit No.		Description
Exhibit 99.1		Press release dated March 17 , 2015: Shantha will provide up to 37 million doses of Shan5™
Exhibit 99.2		Press release dated March 15 , 2015: Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (TM) (alirocumab) Published in The New England Journal of Medicine
Exhibit 99.3		Press release dated March 12, 2015: Filing of the 2014 U.S. Form 20-F and French “Document de Référence” containing the Annual Financial Report
Exhibit 99.4		Press release dated March 6, 2015: Sanofi Appoints Robert Castaigne as Audit Committee Chairman

 

4